Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma
The purpose of this study is to evaluate the safety and efficacy of ARO-HIF2 injection (also referred to as ARO-HIF2) and to determine the recommended Phase 2 dose in the treatment of patients with advanced clear cell renal cell carcinoma (ccRCC).
Clear Cell Renal Cell Carcinoma
DRUG: ARO-HIF2
Number of Participants with Adverse Events (AEs) Possibly or Probably Related to Treatment, Up to 2 years from first dose
Pharmacokinetics (PK) of ARO-HIF2: Maximum Observed Plasma Concentration (Cmax), Up to Week 2: predose and up to 48 hours postdose|PK of ARO-HIF2: Time to Maximum Plasma Concentration (Tmax), Up to Week 2: predose and up to 48 hours postdose|PK of ARO-HIF2: Area Under the Plasma Concentration Versus Time Curve from Zero to 4 Hours (AUC0-4), Up to Week 2: predose and up to 48 hours postdose|PK of ARO-HIF2: Area Under the Plasma Concentration Versus Time Curve from Zero to 24 Hours (AUC0-24), Up to Week 2: predose and up to 48 hours postdose|PK of ARO-HIF2: Area Under the Plasma Concentration Versus Time Curve from Zero to the Last Measurable Concentration at a Time=t, Using a Specified Trapezoidal Rule (AUC0-t), Up to Week 2: predose and up to 48 hours postdose|PK of ARO-HIF2: Area Under the Plasma Concentration Versus Time Curve from Zero to Infinity (AUCinf), Up to Week 2: predose and up to 48 hours postdose|PK of ARO-HIF2: Terminal Elimination Half-Life (t1/2), Up to Week 2: predose and up to 48 hours postdose|Systemic Clearance Derived From Intravenous Dose/Area Under the Plasma Concentration Versus Time Curve (CL), Up to Week 2: predose and up to 48 hours postdose|Amount of Drug Excreted in the Urine Over One Dosing Interval Through 4 Hours Post- Dose (Ae, 0-4), Up to Week 2: predose and up to 48 hours postdose|Renal Clearance Calculated by Ae, 0-4 h/AUC0-4h (CLR), Up to Week 2: predose and up to 48 hours postdose|Fraction Excreted (or Equivalently the Percent of Dose Excreted) in the Urine, Calculated by 100 X (Ae, 0-4 h/Dose), Up to Week 2: predose and up to 48 hours postdose|Overall Response Rate, Percentage of participants with a best overall response of complete response (CR) or partial response (PR) by Response Evaluation Criteria in Solid Tumors (RECIST) V1.1 criteria., Baseline until disease progression, up to 2 years|Duration of Response, Baseline until disease progression, up to 2 years|Time to Response, Baseline until disease progression, up to 2 years|Progression Free Survival, up to 2 years|Overall Survival, up to 2 years
The purpose of this study is to evaluate the safety and efficacy of ARO-HIF2 injection (also referred to as ARO-HIF2) and to determine the recommended Phase 2 dose in the treatment of patients with advanced clear cell renal cell carcinoma (ccRCC).